A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/415 (2006.01) A61K 9/00 (2006.01) A61K 31/12 (2006.01) A61K 31/122 (2006.01) A61K 31/352 (2006.01) A61K 31/353 (2006.01) A61K 31/365 (2006.01) A61K 31/38 (2006.01) A61K 31/42 (2006.01) A61K 31/435 (2006.01) A61K 31/44 (2006.01) A61K 31/4418 (2006.01) A61K 31/444 (2006.01) A61K 31/465 (2006.01) A61K 31/47 (2006.01) A61K 31/50 (2006.01) A61K 31/635 (2006.01) A61K 31/74 (2006.01) A61K 45/06 (2006.01) A61K 47/10 (2006.01) A61K 47/14 (2006.01) A61K 47/26 (2006.01) A61K 47/32 (2006.01) A61K 47/38 (2006.01
Patent
CA 2414780
There is provided a pharmaceutical composition suitable for topical administration to an eye which contains a selective COX-2 inhibitory drug or nanoparticles of a drug of low water solubility, in a concentration effective for treatment and/or prophylaxis of a disorder in the eye, and one or more ophthalmically acceptable excipients that reduce rate of removal from the eye such that the composition has an effective residence time of about 2 to about 24 hours. Also provided is a method of treating and/or preventing a disorder in an eye, the method comprising administering to the eye a composition of the invention.
L'invention concerne une composition pharmaceutique conçue pour une administration topique à un oeil, laquelle renferme un médicament inhibiteur sélectif de COX-2 ou des nanoparticules d'un médicament à faible hydrosolubilité, dans une concentration efficace pour le traitement et/ou la prophylaxie d'un trouble oculaire, ainsi qu'un ou plusieurs véhicules acceptables sur le plan ophtalmique permettant de réduire la vitesse de retrait de la composition de l'oeil, de manière que celle-ci présente un temps de résidence efficace compris entre environ 2 et environ 24 heures. L'invention concerne en outre un procédé de traitement et/ou de prévention d'un trouble oculaire, le procédé consistant à administrer une composition selon l'invention à un oeil.
Bandyopadhyay Rebanta
Hawley Leslie C.
Kararli Tugrul T.
Singh Satish K.
Macrae & Co.
Pharmacia & Upjohn Company
LandOfFree
Ophthalmic formulation of a selective cyclooxygenase-2... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ophthalmic formulation of a selective cyclooxygenase-2..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ophthalmic formulation of a selective cyclooxygenase-2... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1346714